Retroviral Replicating Vector Toca 511 (<i>Vocimagene Amiretrorepvec</i>) for Prodrug Activator Gene Therapy of Lung Cancer

Retroviral Replicating Vector Toca 511 (<i>Vocimagene Amiretrorepvec</i>) for Prodrug Activator Gene Therapy of Lung Cancer

Therapeutic efficacy of retroviral replicating vector (RRV)-mediated prodrug activator gene therapy has been demonstrated in a variety of tumor models, but clinical investigation of this approach has so far been restricted to glioma and gastrointestinal malignancies. In the present study, we evaluat...

Full description

Bibliographic Details
Main Authors: Hiroki Kushiya, Kei Hiraoka, Tomohiro Suzuki, Kazuho Inoko, Akihito Inagaki, Hiroki Niwa, Katsunori Sasaki, Toru Nakamura, Takahiro Tsuchikawa, Toshiaki Shichinohe, Douglas J. Jolly, Noriyuki Kasahara, Satoshi Hirano
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Cancers
Subjects:
lung cancer
gene therapy
retrovirus vector
Online Access:https://www.mdpi.com/2072-6694/14/23/5820

Internet

https://www.mdpi.com/2072-6694/14/23/5820

Similar Items